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Abstract: Phenylketonuria (PKU) management is aimed at preventing neurocognitive and
psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended
target range. It can be questioned, however, whether universal plasma phenylalanine target
levels would result in optimal neurocognitive outcomes for all patients, as similar plasma
Nutrients 2 0 1 9 ,11, 2572; doi:10.3390/nu11112572 www.mdpi.com/journal/nutrients
Nutrients 2019, 11, 2572 2 of 10
phenylalanine concentrations do not seem to have the same consequences to the brain for each 
PKU individual. To better understand the inter-individual differences in brain vulnerability to high 
plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU 
patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are 
still alive. In total, we identified 16 such cases. W hile intellectual functioning in these patients 
was relatively unaffected, they often did present other neurological, psychological, and behavioral 
problems. Thereby, these "unusual" PKU patients show that the classical symptomatology of 
untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack 
of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily 
imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases 
may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative 
importance seems to differ between patients and possibly also with increasing age. Further research 
should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma 
phenylalanine concentrations.
Keywords: phenylketonuria; late-treated; untreated; outcome; brain vulnerability; inter-individual
differences
1. Introduction
Phenylketonuria (PKU; OMIM 261600) management is aimed at reducing plasma phenylalanine 
(Phe) concentrations as timely as possible and further keeping them within the recommended target 
range [1- 3]. None of these guidelines take personalized medicine as a starting point, whereas it can 
be questioned whether universal plasma Phe target levels would result in optimal neurocognitive 
outcomes for all individual PKU patients. Similar plasma Phe concentrations do not seem to have the 
same consequences to the brain for each PKU individual. While the usual picture of untreated PKU 
includes developmental delay in development, resulting in severe intellectual disability and behavioral 
problems, this does not seem to be the case for all PKU patients. The most distinctive examples of this 
are the (often old) reports of untreated or late-diagnosed PKU patients, who have somehow escaped 
from intellectual disability despite high plasma Phe concentrations [4]. The mechanism underlying 
these differences in intellectual outcome between PKU patients still remains to be elucidated, as well 
as its implications for the optimal treatment of PKU individuals.
To better understand the inter-individual differences in brain vulnerability to high plasma 
Phe concentrations, PKU patients with a phenotype of a low vulnerability to high plasma Phe 
concentrations with respect to neurocognition would be informative and worth investigating in further 
detail. Therefore, as a first step, we aimed to identify such "unusual" PKU patients who are still 
alive, being untreated and/or late-diagnosed PKU patients with (near-)normal neurocognitive outcome 
despite high plasma Phe concentrations, to investigate their outcome with regard to other brain 
functions. Here, we describe 16 cases of such "unusual" PKU patients.
2. Cases
To identify PKU patients with unexpected favorable outcomes despite being untreated or 
late-diagnosed with high plasma Phe concentrations, who had not been described previously, 
we contacted physicians and dietitians personally, through a request on the metab-l server, and 
by presenting the idea for this study at the SSIEM (Society for the Study of Inborn Errors of Metabolism) 
and ESPKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria) 
in 2016. In total, we identified 16 cases of late-diagnosed PKU patients without intellectual disability 
despite high plasma Phe concentrations (>1200 pmol/L). Identified cases were diagnosed with PKU 
either following the diagnosis in an affected sibling (n = 4), because of a child of the mother being
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diagnosed with PKU by newborn screening or the maternal PKU syndrome (n = 6), or because of 
mental or neurological deterioration at a later age (n = 4). The most illustrative cases are presented 
here (Table 1). Other cases are described as Supplemental Material.
2.1. Detected through Affected Sibling
Cases 1A and 1B were born as the daughter (1A) and son (1B) of two non-consanguineous 
Dutch parents before the introduction of newborn screening. The boy presented at the age of 
2 years and 1 month with developmental delay. His plasma Phe concentration was 1700 pmol/L 
and his electroencephalography (EEG) showed diffuse changes in cerebral functioning with 
epileptic features, without a clinical history of seizures. Dietary treatment was promptly initiated, 
and a neuropsychological examination 4 months later showed a developmental quotient (DQ) of 
33. Genetic testing showed compound heterozygosity for the PAH variants c.829T > G/p.Y277D and 
c.1315+1G > A/p.IVS12+1G > A. Some years later, his elder sister, 1A, was also investigated and 
unexpectedly found at the age of 8 years and 10 months to have PKU with a plasma Phe concentration 
of 1800 pmol/L. The neurological examination showed no abnormalities. At school, she was noted to 
be slow and have difficulties focusing, but otherwise she was a normally developing child. Formal 
evaluation 2 months after the initiation of dietary treatment revealed neurocognitive functioning 
within the normal range. Subsequent evaluations at age 13 years and 49 years showed an IQ of 102 and 
105, respectively, while treatment has always been problematic and was completely abandoned from 
35 years of age. In contrast, neuropsychological evaluations of 1B at age 5 years and 9 months, 6 years 
and 6 months, 12 years, 40 years, and 47 years showed DQs/IQs of 72 ,87 ,99 , 79, and 105, respectively, 
as assessed by different neuropsychological instruments.
Case 2 is a female originating from the USA who was unexpectedly found to have a blood Phe 
concentration of 2400 pmol/L at 9 years of age, after her younger brother had been diagnosed with PKU 
as part of an evaluation for severe intellectual disability at 3 years of age. She had no history of seizures 
and showed a (low-)normal IQ. No dietary treatment was applied. In contrast to her brother, who was 
institutionalized, she finished high school. However, she was unable to hold jobs due to behavioral 
issues. At 44 years of age, she presented with intermittent headaches, astigmatism, poor focus, anger 
outbursts, anxiety, depression, panic attacks, and episodes of screaming and disorientation at night. 
The blood Phe concentration at that time was 1651 pmol/L, which effectively decreased following the 
institution of dietary treatment.
Cases 3A and 3B were born as the children of healthy Polish parents. The eldest (3A) is a girl 
who first showed some mildly delayed psychomotor development, but later obtained very good 
results at school. At 10 years of age, she was unexpectedly found to have a plasma Phe concentration 
of >1200 pmol/L, after her younger brother (3B) had been diagnosed with PKU. His psychomotor 
development had been retarded: he sat alone at 12 months, walked at 17 months, and said his first 
words at 4 years of age. In addition, he showed hyperactivity and excessive mobility. At 4.5 years of 
age, he was investigated by the neurologist because of speech delay, which revealed a plasma Phe 
concentration of 2100 pmol/L. Following diagnosis in both children, dietary treatment was instituted in 
both patients. The older sister obtained a linguistic higher-education degree, and the younger brother 
obtained very good results at school, as well. Genetic analyses showed a compound heterozygosity for 
the PAH variants c.1222C > T/p.R408W and c.782G > A/p.R261Q.
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Table 1. Cases of late-diagnosed PKU patients who have escaped from intellectual disability despite high plasma Phe concentrations.
Case
Age at Phe PAH
IQ
N eurological Psychological/Psychiatric/Social Other InvestigationsD iagnosis (M/F) (p.mol/L) M utation Norm al Findings Abnorm al Findings Norm al Findings Abnorm al Findings
1A 8 years and 10 
months (F)







Slow at school and has 
difficulties focusing
2 9 years (F) 2400 unknown (low-) normal




and astigmatism from 
the age of 44
Poor focus, anger 
outbursts, anxiety, 
depression, panic 
attacks, and episodes of 
screaming and 
disorientation at night 
from 44 years of age
Unable to hold jobs 
due to behavioural 
issues
3A 10 years (F) >1200
c.1222C > 
T/p.R408W 




















rigidity, and tremors 





age range of 50s-60s
MRI brain in 60s: mild 
generalized cerebral 
atrophy and moderate 
T2 white matter 
hyperintensities
5 23 years (F) 1293
c.1222C > 
T/p.R408W 








learning troubles, and 
polyneuropathy
Employed
Distrustful on the 





EEG: irritative changes 
with residual 
encephalopathy 
CT brain: no 
abnormalities
High school




















with bilateral white 
matter hyperintensities
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Table 1. Cont.
Case
Age at Phe PAH
IQ
N eurological Psychological/Psychiatric/Social Other Investigations
D iagnosis (M/F) (pmol/L) M utation Norm al Findings Abnorm al Findings Norm al Findings Abnorm al Findings
Headache and
increasing difficulty 
with practical tasks MRI brain: extensive






from 41 years of age. 








tiredness, and lack of 
energy from 41 years 
of age
white matter changes 




Social phobia. MRI brain: extensive






No history of 
seizures
Tremor and slight gait 
problems from 
adolescence







strong verbal and 
reasoning abilities







PKU: phenylketonuria; M/F: male/female; PAH: phenylalanine hydroxylase; IQ: intelligence quotient; MRI: m agnetic resonance imaging; EEG: electroencephalography; CT: computed 
tom ography scan.
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2.2. Mothers Detected through Their Child Suffering from  PKU or the Maternal PKU Syndrome
Case 4 is a woman of (low-)normal intelligence from New Zealand who had completed high school 
and has worked as an enrolled nurse. She presented at the age of 27 years after she had given birth to a 
child with features of the maternal PKU syndrome. She was diagnosed with PKU with a plasma Phe 
concentration of 1500 gmol/L, which was confirmed by a genetic analysis that showed a compound 
heterozygosity for the c.311C > A/p.A104D and c.1315+1G > A/p.L249F PAH variants. Treatment was 
not started until the age of 46 years. On dietary treatment, with plasma Phe concentrations <400 pmol/L, 
she started to show some deterioration in function. Therefore, treatment was discontinued at 49 
years of age, but she continued to deteriorate during her 50s and early 60s, showing moderate/severe 
intellectual disability, Parkinson's features, rigidity, tremors, and depression. Cerebrospinal fluid 
(CSF) analysis showed a Phe concentration of 490 pmol/L (reference values: 2-19 pmol/L), a tyrosine 
concentration of 22 pmol/L (reference values: 2-14 pmol/l), and a glutamine concentration of 776 gmol/L 
(reference values: 284-566 gmol/L) at plasma concentrations of respectively 1521, 64, and 502 gmol/L. 
Other amino acid concentrations in CSF were normal. Magnetic resonance imaging (MRI) showed 
mild generalized cerebral atrophy and moderate T2 white matter hyperintensities.
Case 5 is a Moldovan woman who completed general school till high school (9 classes) and 
is employed. She has a history of frequent headaches, intracranial hypertensive syndrome, some 
learning troubles at school, and irritative changes on EEG, with residual encephalopathy without an 
effect of anticonvulsive treatment. She presented at 23 years of age, after she had given birth to two 
children who had died because of congenital heart malformations. Because of her gynecological history, 
she was investigated for hyperhomocystinemia, which did not only identify elevated homocysteine 
concentrations, but also a plasma Phe concentration of 1293 pmol/L. The diagnosis of PKU was confirmed 
by compound heterozygosity for the PAH variants c.1222C > T/p.R408W and c.143T > C/p.L48S. At 
the moment of diagnosis, she was 4 -5  weeks into her third pregnancy, and she decided to continue 
the pregnancy. Dietary treatment was initiated at 6 -7  weeks of gestation, resulting in plasma Phe 
concentrations within the recommended range from 7-8 weeks of pregnancy onward. Her child was 
born with a very minor aortic coarctation, but suddenly died because of pneumonia. Brain imaging 
by computed tomography (CT) at 25 years of age showed no abnormalities, while neurocognitive 
assessment at 26 years showed an IQ of 81. Neuropsychological/behavioral assessment showed her to 
be distrustful of the motives of others and to have poorly controlled emotions and increased verbal 
aggression (having a grudge and worrying about the reason her children had died). Neurological 
examination revealed polyneuropathy.
2.3. Mental/Neurological Deterioration at Later Age
Case 6 is an Italian female and high school graduate, who presented at the age of 26 years 
with worsening headaches, scintillating scotoma, photophobia, and phonophobia, without a history 
of seizures. As part of the diagnostic workup, she was found to have PKU with a plasma 
Phe concentration of 2580 gmol/L and a compound heterozygosity for the PAH variants c.143T > 
C/p.L48S and c.781C > T/p.R261*. Following the introduction of the Phe-restricted diet, cephalgic 
episodes disappeared. Brain MRI showed leukoencephalopathy with bilateral white matter 
hyperintensities on delayed phase (DP), T2, and fluid-attenuated inversion recovery (FLAIR) in 
ventricular fronto-temporo-parietal and semioval centers. Neurological examination at 34 years of age 
did not show any abnormalities, and she has no behavioral or psychiatric symptoms.
Case 7 is a daughter of a Greek father and Norwegian mother, who was healthy during childhood 
and became an assistant nurse. She has given birth to a daughter who suffers from epilepsy and a 
moderate cognitive defect, as well as two additional children who exhibited microcephaly and a heart 
anomaly and died as newborns. From the age of 41 years, she suffered from headaches, depression, 
anxiety, tiredness, and lack of energy, and she experienced increasing difficulty performing practical 
tasks. She also had short episodes with confusion/loss of memory and involuntary contractions in 
facial muscles. As part of a comprehensive neurological examination at the age of 52 years, she
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showed a plasma Phe concentration of 1700 pmol/L. The diagnosis of PKU was further confirmed 
by compound heterozygosity for the PAH variants c.194T > C/p.I65T and c.311C > A/p.A104D. 
Neuropsychological examination revealed mild cognitive difficulties, mainly affecting attention, 
executive function, and other nonverbal capacities, consistent with diffuse cerebral affection as seen 
in untreated PKU. The brain MRI showed extensive white matter changes with multiple micro 
hemorrhages, and an EEG showed possible epileptogenic activity. On dietary treatment, she exhibited 
a gradual clinical improvement, becoming more energetic and less tired, and having less headaches. 
After one year of dietary treatment, there was a partial improvement of the white matter lesions and 
no epileptogenic activity on EEG. Repeated neurological examinations, however, showed regression of 
pathological findings on the brain MRI and EEG.
Case 8 is an Iranian male who moved to Norway at 10 years of age. He had a history without 
seizures, but suffered from dyslexia and social phobia form an early age. He has a bachelor degree 
in social science, completed studies in Farsi, and published a collection of poems. From adolescence, 
he showed tremor and slight gait problems, and at the age of 29 years, he was found to have a 
plasma Phe concentration of 1400 pmol/L. The diagnosis of PKU was further confirmed by compound 
heterozygosity for the PAH variants c.168G > T/p.E56D and c.782G > A/p.R261Q. A neuropsychological 
examination revealed nonverbal learning difficulties and dyslexia, slow processing speed performance, 
and strong verbal and reasoning abilities, with an IQ score of 82 (WAIS-IV). His brain MRI showed 
extensive signal changes in white matter, and his EEG showed slightly pathologic frontotemporal 
peak potentials, without epileptogenic activity. After initiation of dietary treatment, his attention and 
executive functioning slightly improved, but his tremor and gait problems remained unchanged.
3. Discussion
This study describes 16 cases of PKU patients without ID, despite a late diagnosis with high 
plasma Phe concentrations. Most notable is the fact that we could identify so many cases with favorable 
outcomes that had remained unreported and in which the patients are still alive. The second important 
observation was that, although these patients had intellectual functioning within the normal range, 
many showed other cerebral PKU symptoms, with a large heterogeneity with respect to severity and 
type of cerebral symptoms. The third remarkable finding was that, in some of the PKU patients, 
neurological symptoms only started in adulthood.
The textbook story of PKU states that untreated PKU results in severe intellectual disability, 
seizures, and psychiatric symptoms at an early age. Thanks to the introduction of newborn screening 
and dietary treatment, severe intellectual disability can be prevented [5]. In consequence, the focus 
of research has shifted toward further optimizing treatment. The question arises, however, whether 
further optimizing treatment should not also take into account the "original" natural history of PKU, 
acknowledging the large heterogeneity with respect to both the severity and type of cerebral symptoms.
In 1960, Knox reported that, in a series of n = 466 untreated PKU patients, 64.4% had an IQ < 20 
and 23.2% had an IQ between 21 and 40, while only 12.4% had an IQ > 40 (9.7% had IQs of 41-60; 
1.9% had IQs of 61-80; and 0.6% had IQs > 80) [6]. By this, Knox did not only show the severity of IQ 
impairment, but also the heterogeneity of the effect of PKU on intellectual functioning. By reviewing the 
literature, we recently identified 59 "unusual" reported cases of late-diagnosed PKU patients without 
severe intellectual disability despite high plasma Phe concentrations [4], clearly demonstrating that the 
severity of brain dysfunction is different for individual PKU patients. As reported here, we were able to 
identify 16 additional (and previously unreported) cases of "unusual" PKU patients who are still alive. 
With the introduction of newborn screening in the 1960s and 1970 in most developed countries, one 
might say that these phenotypical differences between untreated PKU patients have become irrelevant. 
However, the biological mechanisms underlying these differences in brain vulnerability to high plasma 
Phe concentrations should still be present in today's population of early treated PKU patients, though 
being even more difficult to identify. If we aim to further optimize PKU treatment, we thus need to take 
into account the heterogeneity of the disease, striving toward personalized medicine, i.e., adjusting
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strictness of treatment to the individual— and, perhaps, age-related—brain vulnerability to high plasma 
Phe concentrations of a patient. To this purpose, the "unusual" late-diagnosed PKU patients described 
here may be really helpful.
These "unusual" PKU patients, representing one end of the phenotypic spectrum with regard to 
neurocognitive outcome in relation to plasma Phe levels, can contribute to our understanding of the 
relationship between plasma Phe concentrations and brain dysfunction. While the cases described in 
the present study were selected based on the presence of a relatively normal IQ, many still showed other 
neurological or psychiatric symptoms. This could be explained by either one or the combination of the 
following two hypotheses: (1) a generally lower brain vulnerability to high plasma Phe concentrations 
(possibly due to abnormal transport of Phe from blood to brain or into the neuronal cells) that would 
prevent (severe) intellectual disability but would still be accompanied by milder cerebral symptoms; 
or (2) an escape mechanism in one of the metabolic/molecular pathways in the brain, mediating the 
cerebral responses to high brain Phe concentrations that would prevent certain PKU symptoms (such as 
intellectual disability), while other symptoms mediated by different pathophysiological mechanisms 
would still occur. The first hypothesis is supported by the fact that, in some late-diagnosed PKU 
patients with an unexpected favorable outcome, magnetic resonance spectroscopy (MRS) assessments 
have shown relatively low brain Phe despite high plasma Phe levels [7,8]. Also, in early treated PKU 
patients, characteristics of brain Phe uptake were shown to correlate with abnormalities of cerebral 
white matter as assessed by MRI, as well as IQ [9,10]. However, in 13 PKU patients with reduced 
brain Phe influx, no DNA polymorphisms were found in the gene encoding for LAT1, the predominant 
transporter for Phe and other large neutral amino acids (LNAA) at the blood-brain barrier (BBB) [11]. 
Moreover, Phe concentrations in CSF of the above-mentioned reported Case 5 were correspondingly 
high with the high plasma Phe concentrations. In relation to the second hypothesis, it is of interest that 
many of the cases presented in this paper showed neurological or psychiatric symptoms that seemed to 
be different from signs and symptoms seen in classical untreated PKU. Remarkably, whereas seizures 
are one of the core symptoms of untreated PKU, approximately half of the cases did not have a history 
of seizures nor EEG abnormalities, so, along with IQ, electrophysiological brain activity seemed to be 
only relatively mildly affected in these "unusual" PKU patients. It would be of interest to see whether 
these patients reveal comparable gray matter abnormalities as seen in early treated PKU patients on 
MRI, as reported by Christ et al. [12]. In contrast, neurological symptoms that were observed more 
frequently in the "unusual" PKU patients included not only tremors, which can be found in early 
treated PKU patients, as well, but also headaches, which are not one of the typically reported PKU 
symptoms. Moreover, many showed one or more psychological, mood, behavioral, and/or social-skill 
problems. In some cases, these problems were even the primary complaint of the patient and the 
reason to seek medical consultation that ultimately led to the diagnosis of PKU [13], acknowledging 
also the possibility that these presenting symptoms are not necessarily due to PKU itself and might 
also be a non-PKU-related comorbidity. Thereby, the mechanism underlying the difference in brain 
vulnerability to high plasma Phe concentrations, as well as the question whether this is due to some 
genetic factor (e.g., a "protective gene" not directly associated with the PAH genotype), still remains to 
be elucidated.
Such differences in cerebral problems resulting from high plasma Phe concentrations is not 
only observed between individual PKU patients, but also in relation to age, as the clinical picture of 
suboptimally treated PKU seems to evolve with aging. While high plasma Phe concentrations during 
childhood are known to primarily affect intellectual functioning, increased plasma Phe concentrations 
during adolescence seem to result in behavioral issues and executive dysfunction, and during adulthood, 
they seem to be primarily associated with neurological, psychological, mood, and behavioral problems, 
as well as deficits in social skills [14- 16]. In addition, several cases reported here of neurological 
and/or psychosocial problems that only started in adulthood and thereby led to the late diagnosis 
of PKU suggest that the adult or aging brain may be more vulnerable to some of these particular 
pathophysiological mechanisms. While the "unusual" PKU patients somehow seem to be protected
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against the development of intellectual disability during childhood, these patients may not be protected 
against other PKU symptoms, including in adulthood.
To conclude, considering the limitations of this study— including a series of case studies with 
often incomplete clinical documentation and different treatment approaches throughout life—the 16 
cases of late-diagnosed and late-treated PKU patients with unexpected favorable intellectual outcomes 
despite high plasma Phe concentrations, as presented in this study, provide further insight into the 
inter-individual differences in brain dysfunction of PKU patients. W hile intellectual functioning 
in these patients was relatively unaffected, remarkably, they often did present other neurological, 
psychological, and behavioral problems. Thereby, these "unusual" PKU patients show that the classical 
symptomatology of untreated or late-treated PKU may have to be rewritten, not only in the sense that 
intellectual dysfunction is not obligatory, but also in the sense that intellectual functioning does not 
(re)present the full picture of brain damage due to high plasma Phe concentrations. Furthermore, this 
may suggest that different mechanisms are involved in the pathophysiology underlying the full clinical 
entity of brain dysfunction in PKU patients, of which the relative importance seems to differ between 
patients and possibly also with increased age. In a way, these "unusual" PKU patients are similar to 
the treated PKU adults who do not really encounter neurocognitive problems, but rather show mood, 
behavioral, and social-skill issues [14,16]. Further research should aim to better distinguish between 
PKU patients with respect to their cerebral reactions to high plasma Phe concentrations, including 
in relation to aging. Investigations to this purpose are underway on both a genetic and functional 
level, using material of some of the "unusual" PKU patients mentioned in this paper, but also still 
welcoming material of additional "unusual" PKU patients.
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